A Study of Mirikizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab.
The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.
The study will last about 23 weeks for each participant, which includes 10 outpatient visits and 2 inpatient visits (with 3 overnights per visit).
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participants must have chronic plaque psoriasis for at least 6 months and are candidates for treatment with a prescription drug or light therapy
- Participants must have moderate to severe plaque psoriasis, as determined by the investigator
- Participants must not be pregnant or nursing (breastfeeding)
- Participants must not have a history of an ongoing, chronic or recurrent infection, or evidence of tuberculosis
- Participants must not have had major surgery within 8 weeks prior to first admission to the clinical site or during the study
- Participants must not have a history of lymphoma (cancer of the lymph nodes), leukemia (blood cancer), or any other cancer
- Participants must not require treatment with any drug given during the study. These include midazolam (sedative), warfarin (blood thinner), dextromethorphan (cough suppressant), omeprazole (stomach acid reducer) and caffeine
- Participants must not have participated in any other research study with the study drug known as mirikizumab